Trio Medicines (United Kingdom)
Trio Medicines Ltd (“Trio”) was founded in 2007 by HMR Ltd, London, UK, a contract research organisation, and the late Sir James Black (Nobel Laureate) who invented two classes of medicines, β-blockers and histamine H2-blockers. The original aim of Trio was to develop netazepide, a gastrin/CCK2 receptor antagonist, for clinical use. In addition to netazepide, a gastrin/CCK2 receptor antagonist, Trio is now developing three other molecules: ceclazepide, a second gastrin/CCK2 receptor antagonist;
Basic Information
- Category: business
- Founded: 2007
- Website: http://www.triomedicines.com/
Documented Facts
- Email: trio@triomedicines.com (No linked source recorded for this statement.)
- Founded: 2007 (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Trio Medicines (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/trio-medicines-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/trio-medicines-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/trio-medicines-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (80/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Trio Medicines Ltd (“Trio”) was founded in 2007 by HMR Ltd, London, UK, a contract research organisation, and the late Sir James Black (Nobel Laureate) who invented two classes of medicines, β-blockers and histamine H2-blockers. The original aim of Trio was to develop netazepide, a gastrin/CCK2 receptor antagonist, for clinical use. In addition to netazepide, a gastrin/CCK2 receptor antagonist, Trio is now developing three other molecules: ceclazepide, a second gastrin/CCK2 receptor antagonist;
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.